Abstract Body

Background

A neuroactive steroid (NAS) analog is FDA-approved for postpartum depression and shows efficacy in major depressive disorder (MDD) in people without HIV (PWoH). Pregnenolone, a NAS precursor, exerts anti-inflammatory effects in myeloid cell lines after Toll-like receptor (TLR) stimulation, but its modulation of cytokine production in people with HIV (PWH) is unknown. 

Methods

Endogenous plasma NAS were quantified by mass spectrometry in 20 PWoH (9F,11M) and 33 PWH (8F,25M; viral load <200 copies/mL). Associations between pregnenolone and plasma cytokines were assessed using Pearson correlations. Peripheral blood mononuclear cells from 4 PWoH (2F,2M) and 5 PWH (3M,2F) were stimulated with TLR4 agonist LPS or TLR2/1 agonist Pam3CSK4 overnight, then treated with pregnenolone (4000 pg/mL, 10 µM, or 50 µM) for 6 hours with brefeldin A. Phenotypic markers and intracellular cytokine expression in monocyte subsets were quantified by flow cytometry, and effects were analyzed by two-way ANOVA with Dunnett’s multiple comparison test. 

Results

Higher pregnenolone levels correlated with lower plasma IL-6 (r=–0.60, p<0.01) and TNFα (r=–0.33, p=0.02) in the full cohort, with similar associations in PWH in vivo. After LPS stimulation in vitro, pregnenolone (50 µM) reduced TNFα and IL-6 in classical (CD14⁺CD16⁻) monocytes (Padj<0.01) and increased TGF-β (10 & 50 µM) and IL-10 (50 µM) in the same subset (Padj <0.01). In intermediate (CD14⁺CD16⁺) monocytes, pregnenolone decreased IL-6 at 10 µM and 50 µM (Padj≤0.01), while increasing TGF-β, IL-10, and TNFα. Following Pam3CSK4, pregnenolone similarly decreased IL-6 and increased TGF-β in classical and intermediate monocytes (Padj<0.05), with TNFα increased in classical monocytes and IL-10 increased in intermediate cells (Padj <0.01, both). UMAP visualization highlighted distinct shifts in cytokine profiles of monocytes after LPS stimulation; these shifts remained consistent between HIV+ and uninfected cells (Fig 1). 

Conclusions

Pregnenolone consistently reduced IL-6 and enhanced regulatory cytokines (IL-10, TGF-β) across monocyte subsets, while effects on TNFα varied by TLR agonist and monocyte subset. These data suggest that pregnenolone promotes a more regulatory immune phenotype in PWH. An ongoing clinical trial is assessing the role of pregnenolone in PWH and MDD (NCT05570812). 

Table or Figure